Oxford BioMedica PLC (OXBDF)

[marcusl2]

CTL-019 BLAs awarded for: paediatric r/r B-ALL and paediatric/adult DLBCL by
2Q’18
? CTL-019 treatment mainly in relapsed/refractory patients with poor prognosis:
10% B-ALL patients and 30% DLBCL patients
? Max 20% penetration of the ALL market in Europe and 30% in US; max 15%
penetration of the DLBCL market in Europe and 25% in US by 2025
? Price for single treatment: $600,000
? OXB receives 4% royalties
We estimate that Novartis will achieve sales of $2.05bn per annum from CTL-019 by
2025. OXB could, therefore, receive a total of $82.0m in royalties per annum, in
addition to manufacturing revenue.

HTTP://www.hardmanandco.com/docs/default-source/company-docs/oxford-biomedica-documents/31.03.17-delivering-commercial-gene-therapy-vector.pdf